LSTM Home > LSTM Research > LSTM Online Archive

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential.

Fernandez, Cristina and van Halsema, Clare (2019) 'Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential.'. HIV/AIDS : Research and Palliative Care, Vol 11, pp. 179-192.

[img]
Preview
Text
hiv-184642-evaluating-cabotegravir-rilpivirine-long-acting-injectable-.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (364kB) | Preview

Abstract

Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. Adding to the increasing body of evidence for newer two-drug combinations, phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most importantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-weekly injections, despite frequent injection-site reactions. Key outstanding questions include management of missed or delayed dosing, drug interactions and management of virological failure, as well as the efficacy of cabotegravir and rilpivirine in all HIV-1 subtypes. We describe clinical evidence to date and efficacy and challenges in selected populations, including women; those with prior virological failure; individuals with a history of difficulty adhering to oral therapy and individuals with co-infections. We await real-world data and longer-term evidence while moving forward to this new era of antiretroviral therapy.

Item Type: Article
Subjects: WA Public Health > Health Problems of Special Population Groups > WA 395 Health in developing countries
WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503 Acquired immunodeficiency syndrome. HIV infections
WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503.2 Therapy
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Education
Digital Object Identifer (DOI): https://doi.org/10.2147/HIV.S184642
Depositing User: Stacy Murtagh
Date Deposited: 27 Aug 2019 12:47
Last Modified: 29 Aug 2019 09:32
URI: https://archive.lstmed.ac.uk/id/eprint/11513

Statistics

View details

Actions (login required)

Edit Item Edit Item